{"meta":{"query_hash":"c3179db2e965","filters":{"venue":"Immuno-Oncology Technology"},"cohort_total":41,"direct_labels_cover":0,"predictions_cover":41,"exported":41,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/c3179db2e965","api":"https://metacan.xera.ac/api/v1/cohort?venue=Immuno-Oncology+Technology"},"results":[{"id":"W4310923624","doi":"10.1016/j.iotech.2022.100230","title":"241P Treatment and outcomes of patients with gastrointestinal toxicity following immunotherapy: A large multi-center retrospective study in the United Kingdom by the National Oncology Trainees Collaborative for Healthcare Research (NOTCH)","year":2022,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Center (category theory); Retrospective cohort study; Health care; Immunotherapy; Toxicity; Internal medicine; Family medicine; Oncology; Cancer; Political science","score_opus":0.059524769806824473,"score_gpt":0.4100764466070851,"score_spread":0.3505516768002606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310923624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963581,0.002045278,0.00007100901,0.00009979964,0.000010867819,0.000012108745,0.00096828997,0.0000029129467,0.00043175925],"genre_scores_gemma":[0.99846053,0.00034533898,0.000033048414,0.00009503799,0.000014027678,0.000011785686,0.0009229934,0.000003269797,0.00011404515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990331,0.00023139948,0.00015112752,0.00026217542,0.00015659751,0.00016562849],"domain_scores_gemma":[0.9977719,0.00034232982,0.0012127962,0.00016929636,0.00022376698,0.00027996144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005655543,0.00026586375,0.00065918034,0.0004572564,0.0004936918,0.0009746802,0.0003655994,0.00067598844,0.001462032],"category_scores_gemma":[0.0021114582,0.0003512338,0.00090679293,0.0014972086,0.00033626222,0.0004997515,0.0005890875,0.00079773465,0.00026830347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048413055,0.00001844607,0.9976676,0.00003320983,0.00017890184,0.00018886199,0.00004508485,0.000034788038,0.0001814061,0.000015459771,0.00021290878,0.00093917863],"study_design_scores_gemma":[0.000028270204,0.0001515047,0.9985909,0.00001767047,0.00010057501,0.00054589356,0.00010082297,0.000057973954,0.000046457735,0.000011717155,0.00034163625,0.0000065025743],"about_ca_topic_score_codex":0.0068359296,"about_ca_topic_score_gemma":0.0067155613,"teacher_disagreement_score":0.0068359296,"about_ca_system_score_codex":0.0008713225,"about_ca_system_score_gemma":0.00048448364,"threshold_uncertainty_score":0.013592303},"labels":[],"label_agreement":null},{"id":"W4310923924","doi":"10.1016/j.iotech.2022.100213","title":"109P Impact of anti-drug antibody (ADA) on naxitamab efficacy and safety","year":2022,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Drug; Medicine; Pharmacology","score_opus":0.014692821784628659,"score_gpt":0.3674672308365919,"score_spread":0.3527744090519632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310923924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8498021,0.029036747,0.004471687,0.011760732,0.0014397345,0.0012726312,0.008241002,0.00036567618,0.09360972],"genre_scores_gemma":[0.9770871,0.004589999,0.002326135,0.002674902,0.00029898516,0.00039099282,0.002372411,0.0000921362,0.010167371],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989774,0.00038332236,0.000066178654,0.00007522045,0.00038666604,0.00011117105],"domain_scores_gemma":[0.99897635,0.00049701333,0.00015502163,0.0000619048,0.00019243232,0.00011725864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012851665,0.00018467166,0.00050475943,0.00016547108,0.00019672698,0.0008339504,0.00032021216,0.00056518975,0.015563104],"category_scores_gemma":[0.00287929,0.000107933294,0.0005207421,0.00020776202,0.00035833963,0.00033734654,0.00026943625,0.0013684728,0.0019374093],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032903742,0.0029313006,0.017855031,0.0017182931,0.000762148,0.001052441,0.00012137302,0.0023452607,0.1252463,0.0037620843,0.05597731,0.7553248],"study_design_scores_gemma":[0.017735362,0.14881146,0.17603776,0.0012350401,0.0021149034,0.006158533,0.0002954706,0.012682269,0.2419503,0.006240875,0.38661337,0.0001246314],"about_ca_topic_score_codex":0.0014210592,"about_ca_topic_score_gemma":0.0023769995,"teacher_disagreement_score":0.015563104,"about_ca_system_score_codex":0.0007979171,"about_ca_system_score_gemma":0.0008248267,"threshold_uncertainty_score":0.052063763},"labels":[],"label_agreement":null},{"id":"W4311139822","doi":"10.1016/j.iotech.2022.100303","title":"191P Preliminary biomarker and safety results of SQZ-PBMC-HPV at RP2D in monotherapy and combination with checkpoint inhibitors in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors","year":2022,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Pharmacodynamics; Immunotherapy; Peripheral blood mononuclear cell; Cancer; Antigen; Immunology; Pharmacokinetics","score_opus":0.007143621557407641,"score_gpt":0.27518211663172687,"score_spread":0.2680384950743192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311139822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98378366,0.005418576,0.002359274,0.0007203835,0.0001530798,0.00034843906,0.0019486763,0.00015994534,0.005108106],"genre_scores_gemma":[0.9924585,0.0008748559,0.0009008076,0.0003880188,0.00008518514,0.00015354384,0.0023793732,0.000023697328,0.0027360807],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996327,0.00011400037,0.000025318574,0.00008138992,0.00008699863,0.00005958687],"domain_scores_gemma":[0.9993506,0.0002240973,0.00012514512,0.00006188076,0.00010953747,0.00012880674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078197056,0.00044188643,0.00080516277,0.0002926267,0.00019334309,0.0005359356,0.00018643933,0.00052350416,0.002606778],"category_scores_gemma":[0.00094794814,0.0001399883,0.0007038296,0.00026118435,0.00026408647,0.00036743312,0.00014751614,0.0011202738,0.0005967239],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.136098,0.008276695,0.07803444,0.00078897685,0.0014908545,0.0020446165,0.0003976846,0.00455165,0.45359254,0.00044616664,0.0062163095,0.30806205],"study_design_scores_gemma":[0.009678215,0.4689907,0.18677834,0.0001140399,0.002858482,0.0056606284,0.00029766784,0.007119543,0.2837333,0.00089115696,0.033762496,0.00011537404],"about_ca_topic_score_codex":0.00041537854,"about_ca_topic_score_gemma":0.00059814035,"teacher_disagreement_score":0.002606778,"about_ca_system_score_codex":0.00039932234,"about_ca_system_score_gemma":0.00034845193,"threshold_uncertainty_score":0.008720517},"labels":[],"label_agreement":null},{"id":"W4389480655","doi":"10.1016/j.iotech.2023.100692","title":"LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Symphogen; Astellas Pharma; Gilead Sciences; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Durvalumab; Internal medicine; Neutropenia; Gastroenterology; Etoposide; Cancer; Chemotherapy; Immunotherapy; Pembrolizumab","score_opus":0.032707548856386964,"score_gpt":0.3655740603058458,"score_spread":0.3328665114494589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389480655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98600477,0.005467269,0.0004981833,0.00036688216,0.000060973496,0.00062168797,0.0026734567,0.00014680291,0.0041600466],"genre_scores_gemma":[0.9900934,0.0016510417,0.0007990863,0.000477647,0.000044706358,0.000386032,0.004104325,0.000024724513,0.002419042],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99978644,0.000107546875,0.0000103083985,0.00002986164,0.000031666797,0.000034227367],"domain_scores_gemma":[0.9997826,0.000037592446,0.0000554829,0.000020972311,0.000015046196,0.00008828175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008755853,0.0002823187,0.000828456,0.00022599955,0.00015776402,0.0005847388,0.00040868644,0.00028082795,0.003050161],"category_scores_gemma":[0.0005554331,0.000165381,0.0005352491,0.00025161824,0.00021900541,0.00038919903,0.0001855862,0.0009520729,0.0006350526],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3677121,0.017023016,0.05628551,0.0017673749,0.0021138107,0.00037822805,0.00027212247,0.005351107,0.046966888,0.0005971396,0.02348013,0.47805265],"study_design_scores_gemma":[0.34006643,0.39046597,0.20076777,0.00030132695,0.002802701,0.0019763105,0.00028399768,0.00888904,0.018533528,0.00080294133,0.03502852,0.00008148329],"about_ca_topic_score_codex":0.0011949508,"about_ca_topic_score_gemma":0.0058443397,"teacher_disagreement_score":0.003050161,"about_ca_system_score_codex":0.0007893299,"about_ca_system_score_gemma":0.00065694575,"threshold_uncertainty_score":0.010203779},"labels":[],"label_agreement":null},{"id":"W4389480683","doi":"10.1016/j.iotech.2023.100693","title":"LBA3 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic NSCLC (mNSCLC): 5-year (y) overall survival (OS) update from the POSEIDON study","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Internal medicine; Durvalumab; Regimen; Chemotherapy; Gastroenterology; Progression-free survival; Nuclear medicine; Confidence interval; Oncology; Immunotherapy; Pembrolizumab; Cancer","score_opus":0.025379405179619445,"score_gpt":0.3139009496148696,"score_spread":0.28852154443525013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389480683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98864913,0.007974375,0.0003731019,0.00025210547,0.00007408841,0.00024265818,0.0008899636,0.00005303335,0.001491487],"genre_scores_gemma":[0.99185294,0.0040155402,0.0007131403,0.0003692955,0.000055608085,0.00025837345,0.0014964159,0.000016132362,0.0012226484],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99979264,0.00009551337,0.000015743371,0.00002781072,0.000030142022,0.000038136714],"domain_scores_gemma":[0.9997732,0.00005363866,0.000058362923,0.00001846069,0.000013790875,0.000082516875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001255378,0.00031505013,0.0011192429,0.00016425029,0.00017087441,0.0005096843,0.00035661517,0.00027847188,0.0015780269],"category_scores_gemma":[0.00037482742,0.0001349875,0.00078689284,0.00023068878,0.00024309629,0.00032100108,0.00019230596,0.0009757046,0.00037771117],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3847532,0.011545427,0.02632907,0.0013407394,0.0017144224,0.00020974163,0.000243017,0.0030516838,0.053292714,0.00047070242,0.007227376,0.509822],"study_design_scores_gemma":[0.21626021,0.55872947,0.16427398,0.00026775026,0.003681558,0.0014722967,0.00019402454,0.0046271463,0.024261096,0.0009715703,0.02516835,0.00009255346],"about_ca_topic_score_codex":0.0008838241,"about_ca_topic_score_gemma":0.004103782,"teacher_disagreement_score":0.0015780269,"about_ca_system_score_codex":0.0005324554,"about_ca_system_score_gemma":0.00050784246,"threshold_uncertainty_score":0.0066391826},"labels":[],"label_agreement":null},{"id":"W4389480748","doi":"10.1016/j.iotech.2023.100601","title":"129P Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Refractory (planetary science); Neuroblastoma; Internal medicine; Population; Bone marrow; Phases of clinical research; Interim analysis; Oncology; Nuclear medicine; Gastroenterology; Clinical trial","score_opus":0.0071836360981520995,"score_gpt":0.2752357812312524,"score_spread":0.26805214513310033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389480748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99591774,0.0015263871,0.00014574932,0.00006712149,0.000010644,0.00018709997,0.0006323317,0.000018233135,0.0014945895],"genre_scores_gemma":[0.99659216,0.00049737946,0.00034357363,0.000111062574,0.000020579804,0.00019184695,0.0016954258,0.0000063143943,0.0005417263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99957377,0.00018381307,0.00003987923,0.00005306625,0.000081169645,0.000068252935],"domain_scores_gemma":[0.9995135,0.00014839906,0.00013307456,0.00003320813,0.00004433867,0.00012745538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015070876,0.00027869712,0.0015319926,0.00037115044,0.00016569227,0.00039586623,0.00020896157,0.00025078165,0.0008469316],"category_scores_gemma":[0.0009169111,0.000114999704,0.00060977205,0.0003179356,0.00019956657,0.0003273464,0.0002707604,0.0005193892,0.00021964489],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23455946,0.0035719743,0.5002889,0.00096801855,0.0025144517,0.0013305465,0.00039260648,0.005076267,0.07894098,0.00028931408,0.004211165,0.16785637],"study_design_scores_gemma":[0.01317896,0.106978,0.8623392,0.000065412,0.0010056648,0.001373972,0.00011100184,0.0027491108,0.006267108,0.0002728288,0.005615346,0.00004340097],"about_ca_topic_score_codex":0.0008236058,"about_ca_topic_score_gemma":0.0028763167,"teacher_disagreement_score":0.0015319926,"about_ca_system_score_codex":0.00049317797,"about_ca_system_score_gemma":0.000510525,"threshold_uncertainty_score":0.007970333},"labels":[],"label_agreement":null},{"id":"W4389480834","doi":"10.1016/j.iotech.2023.100668","title":"157TiP Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech; Ipsen; Sanofi; Bayer HealthCare; F. Hoffmann-La Roche; Incyte; Natera; Amgen; ViiV Healthcare; Eisai; AstraZeneca; Bristol-Myers Squibb","keywords":"Pemetrexed; Pembrolizumab; Medicine; Lung cancer; Chemotherapy; Oncology; KRAS; Internal medicine; Lung; Cancer; Cisplatin; Colorectal cancer; Immunotherapy","score_opus":0.010848026459265988,"score_gpt":0.36124044456600973,"score_spread":0.35039241810674376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389480834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98734456,0.003123881,0.00042700468,0.0004845362,0.00023157509,0.0034861926,0.0015763865,0.00014631104,0.0031795423],"genre_scores_gemma":[0.97718734,0.004539249,0.0018566784,0.0014942125,0.00021665375,0.0033317965,0.0055857548,0.000051411513,0.005736835],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997366,0.00008736388,0.0000153528,0.000054077795,0.00003672056,0.000069881695],"domain_scores_gemma":[0.9995834,0.000040234423,0.000052049338,0.000030262809,0.00003173927,0.00026231864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010419581,0.0014000509,0.0017875701,0.00037711932,0.00031702817,0.0011756977,0.0009753337,0.0012463975,0.0048604193],"category_scores_gemma":[0.00045907524,0.0006787213,0.0014977647,0.0003579932,0.0008002971,0.0007273642,0.00032425587,0.0034691326,0.001540091],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6662543,0.14026757,0.0052587106,0.0019878624,0.0020123143,0.00033528483,0.00028350615,0.002296743,0.07074726,0.0005945044,0.0066154203,0.103346504],"study_design_scores_gemma":[0.49268574,0.48902088,0.00694213,0.00006661181,0.0006270421,0.0003375127,0.000092075294,0.00089425483,0.004434805,0.00020634945,0.0046557877,0.00003688377],"about_ca_topic_score_codex":0.0012764023,"about_ca_topic_score_gemma":0.0040408536,"teacher_disagreement_score":0.0048604193,"about_ca_system_score_codex":0.0009821375,"about_ca_system_score_gemma":0.0019769282,"threshold_uncertainty_score":0.01625979},"labels":[],"label_agreement":null},{"id":"W4389480868","doi":"10.1016/j.iotech.2023.100606","title":"134P A phase I study exploring the safety and tolerability of the small molecule PD-L1 inhibitor INCB099318 in select advanced solid tumors","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Incyte; Sierra Oncology; Da Volterra; Ipsen; Eisai; Bristol-Myers Squibb; AstraZeneca; Carrick Therapeutics; Pfizer; Dr. Falk Pharma; ViiV Healthcare","keywords":"Tolerability; Medicine; Pharmacokinetics; Internal medicine; Adverse effect; Clinical endpoint; Gastroenterology; Oncology; Pharmacology; Clinical trial","score_opus":0.04229348806635307,"score_gpt":0.3719076108827646,"score_spread":0.3296141228164115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389480868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93013144,0.0033414783,0.0040193535,0.0020163958,0.00022031213,0.0059333257,0.034187127,0.00045152893,0.019698985],"genre_scores_gemma":[0.9247515,0.0035650202,0.007263955,0.0023629605,0.00015636008,0.004462042,0.042154826,0.00011855677,0.015164852],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998196,0.000070092545,0.000010113728,0.00002851872,0.00004118709,0.000030523694],"domain_scores_gemma":[0.9997085,0.00007501457,0.000050868894,0.000022612798,0.00004576483,0.00009722596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006272413,0.0004082361,0.00057841477,0.0002503366,0.00024354707,0.000418423,0.00035701267,0.00040678497,0.008786066],"category_scores_gemma":[0.0006203933,0.0001326791,0.00070706935,0.00032124476,0.00019791038,0.00025008252,0.00019947391,0.0015119496,0.0013638331],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21357486,0.028330868,0.021670682,0.001738236,0.0017182659,0.00097310194,0.00013500573,0.004382869,0.13346934,0.00095342845,0.07848437,0.514569],"study_design_scores_gemma":[0.24144432,0.4958096,0.10704493,0.00019978914,0.0015981889,0.003049563,0.00010395473,0.0049202335,0.05225696,0.0011420771,0.09233873,0.00009160762],"about_ca_topic_score_codex":0.0012484363,"about_ca_topic_score_gemma":0.0025940828,"teacher_disagreement_score":0.008786066,"about_ca_system_score_codex":0.00055379356,"about_ca_system_score_gemma":0.00096295174,"threshold_uncertainty_score":0.029392302},"labels":[],"label_agreement":null},{"id":"W4389480990","doi":"10.1016/j.iotech.2023.100488","title":"19P The prognostic value of soluble CD73 in advanced triple-negative breast cancer: An exploratory analysis of the SYNERGY trial","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Stichting Tegen Kanker","keywords":"Breast cancer; Oncology; Triple-negative breast cancer; Internal medicine; Value (mathematics); Exploratory analysis; Medicine; Cancer; Statistics; Mathematics; Computer science; Data science","score_opus":0.010884968383471838,"score_gpt":0.28946558515830495,"score_spread":0.2785806167748331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389480990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438715,0.0021199158,0.00021644926,0.0003756379,0.000063308915,0.00024038076,0.0013667457,0.0000209503,0.0012094743],"genre_scores_gemma":[0.99580437,0.0006777192,0.0003910164,0.00024541502,0.00018127826,0.00028331997,0.0017225893,0.000007806669,0.0006864905],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9992762,0.00043859848,0.00004202211,0.0000930728,0.00007507815,0.00007505031],"domain_scores_gemma":[0.99882287,0.00039374724,0.00031216946,0.00010488496,0.000080810634,0.0002854377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020024602,0.00057023665,0.001085737,0.00019586286,0.00019988249,0.00065724953,0.00027146193,0.00049652724,0.0027345615],"category_scores_gemma":[0.0018074714,0.00017841041,0.0011359975,0.00032930524,0.00031735867,0.00047379895,0.00046403607,0.0010864162,0.00042540193],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8956929,0.0017796091,0.05286537,0.00046817618,0.0039717588,0.0001752347,0.000086750784,0.0009045391,0.0061727664,0.00018330233,0.0025335494,0.03516612],"study_design_scores_gemma":[0.40650263,0.27992988,0.2795298,0.00020036369,0.012722467,0.0009378336,0.00020632212,0.005143577,0.004205378,0.0011778094,0.009368445,0.00007554218],"about_ca_topic_score_codex":0.0003149507,"about_ca_topic_score_gemma":0.00074739166,"teacher_disagreement_score":0.0027345615,"about_ca_system_score_codex":0.00043366497,"about_ca_system_score_gemma":0.00056352443,"threshold_uncertainty_score":0.010590136},"labels":[],"label_agreement":null},{"id":"W4389487695","doi":"10.1016/j.iotech.2023.100587","title":"115TiP MDT-BRIDGE: A phase II study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Genentech; LEO Pharma; Aptitude Health; European Society for Medical Oncology; Novocure; Regeneron Pharmaceuticals; Gilead Sciences; Ipsen; BeiGene; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Neoadjuvant therapy; Internal medicine; Durvalumab; Oncology; Stage (stratigraphy); Chemotherapy; Radiology; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.026196427080774427,"score_gpt":0.35465462112259377,"score_spread":0.32845819404181936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389487695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775698,0.0037070317,0.00093194406,0.0010615973,0.00038798244,0.0058778264,0.003876716,0.00023118789,0.006355882],"genre_scores_gemma":[0.96232533,0.004488101,0.004147479,0.0033904114,0.00029002476,0.0070083495,0.009732023,0.00007699739,0.0085413745],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997726,0.00010384236,0.0000138198575,0.000038206934,0.000028469065,0.00004306423],"domain_scores_gemma":[0.9996107,0.00006229506,0.00006416155,0.000030770134,0.000027141397,0.00020497301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010768658,0.0010933559,0.0014587006,0.00024160916,0.00029788006,0.0009068616,0.0008899892,0.0011432443,0.0059495377],"category_scores_gemma":[0.0007055253,0.0004299693,0.0012048451,0.00030967468,0.00057432154,0.0006330829,0.0003763357,0.0030615358,0.0015154955],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6750806,0.07992527,0.0073409467,0.00262788,0.0026472178,0.00024753375,0.00035024015,0.0024494184,0.0535505,0.00078241166,0.012448774,0.16254917],"study_design_scores_gemma":[0.68883646,0.2920952,0.00894609,0.00008653342,0.0005804518,0.0001973136,0.00006247302,0.0009713709,0.0025658454,0.00022614695,0.0054002916,0.000031700478],"about_ca_topic_score_codex":0.0010823368,"about_ca_topic_score_gemma":0.003322117,"teacher_disagreement_score":0.0059495377,"about_ca_system_score_codex":0.00082317943,"about_ca_system_score_gemma":0.0013366345,"threshold_uncertainty_score":0.019903123},"labels":[],"label_agreement":null},{"id":"W4389487916","doi":"10.1016/j.iotech.2023.100553","title":"81P Real-world experience with docetaxel regimens in metastatic non-squamous (mNSq) non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy (PCT) and an immune checkpoint inhibitor (ICI) in the United States (US)","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"Sanofi","keywords":"Docetaxel; Medicine; Internal medicine; Discontinuation; Oncology; Lung cancer; Chemotherapy; Confidence interval; Progression-free survival; Retrospective cohort study; Response Evaluation Criteria in Solid Tumors; Performance status; Progressive disease","score_opus":0.010998413363552492,"score_gpt":0.31328312008101716,"score_spread":0.30228470671746466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389487916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99873,0.00023561169,0.000061287916,0.00004615251,0.000004179223,0.000019701596,0.00047183022,0.0000020011614,0.0004292017],"genre_scores_gemma":[0.9985663,0.00029333483,0.00009220917,0.00006516075,0.000012103611,0.00001697929,0.0007650214,0.0000022821184,0.00018662539],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994993,0.00014022528,0.00006893641,0.00011386261,0.00009778759,0.000079804515],"domain_scores_gemma":[0.9986051,0.00023629864,0.0007758242,0.000111428984,0.00009434353,0.00017696635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007179138,0.000107491745,0.00024338155,0.00025318004,0.0004085746,0.0008619526,0.00019824223,0.00019417539,0.0008426447],"category_scores_gemma":[0.0022216844,0.00017788298,0.000493801,0.0005278448,0.0002590708,0.00044232028,0.00045584355,0.00037403373,0.00022265676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000792855,0.00021995611,0.9891082,0.000033152806,0.00008937943,0.00044045417,0.00027916546,0.00018393976,0.00037409444,0.00005499233,0.00038215026,0.008041583],"study_design_scores_gemma":[0.00014040477,0.0023649395,0.9875065,0.000035345736,0.00014432266,0.0030967523,0.0007782995,0.0008505886,0.0005883152,0.00008229157,0.004391657,0.00002068124],"about_ca_topic_score_codex":0.0043631173,"about_ca_topic_score_gemma":0.009697439,"teacher_disagreement_score":0.0043631173,"about_ca_system_score_codex":0.0008164221,"about_ca_system_score_gemma":0.00062044506,"threshold_uncertainty_score":0.008675456},"labels":[],"label_agreement":null},{"id":"W4389488043","doi":"10.1016/j.iotech.2023.100537","title":"65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Docetaxel; Medicine; Lenvatinib; Oncology; Chemotherapy; Internal medicine; Lung cancer; Phases of clinical research; Cancer; Immunotherapy","score_opus":0.04270142033337985,"score_gpt":0.3679328438520774,"score_spread":0.32523142351869755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389488043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843313,0.0033600105,0.0006551402,0.0010001644,0.00040778305,0.0025633455,0.0024148058,0.0002055688,0.005061817],"genre_scores_gemma":[0.9733227,0.003466443,0.0021795174,0.0017051701,0.00021180898,0.0035425255,0.004483556,0.00006832887,0.011019947],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996768,0.00013339239,0.0000128628335,0.000052716743,0.00003096464,0.00009321779],"domain_scores_gemma":[0.9995834,0.00005978423,0.000052190502,0.000026750577,0.000026233176,0.0002516031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012936168,0.0015485096,0.0019928045,0.00052339217,0.0003968628,0.0017092892,0.0013319713,0.0015029085,0.0057631256],"category_scores_gemma":[0.00068909617,0.0007576459,0.0018579689,0.00043097348,0.0009587822,0.00093682663,0.00045773658,0.004600973,0.0016936492],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77066827,0.056920815,0.003842488,0.0013298456,0.002876594,0.0002802814,0.00033851026,0.0053000143,0.031734396,0.0010392666,0.008220895,0.11744858],"study_design_scores_gemma":[0.704394,0.27605015,0.00712676,0.00006893422,0.00074736075,0.00022109877,0.00009743317,0.002485244,0.0026806535,0.00043279174,0.00565104,0.00004461875],"about_ca_topic_score_codex":0.003057545,"about_ca_topic_score_gemma":0.0073486646,"teacher_disagreement_score":0.0057631256,"about_ca_system_score_codex":0.001729448,"about_ca_system_score_gemma":0.001989347,"threshold_uncertainty_score":0.01927954},"labels":[],"label_agreement":null},{"id":"W4401502464","doi":"10.1016/j.iotech.2024.100726","title":"Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alethia Biotherapeutics (Canada)","funders":"Sigrid Juséliuksen Säätiö; Jane ja Aatos Erkon Säätiö; European Commission; Helsingin Yliopisto; Les Laboratories Pierre Fabre; Syöpäsäätiö; Novo Nordisk; Sanofi","keywords":"Oncolytic adenovirus; Oncolytic virus; Metastatic melanoma; Melanoma; Mucosal melanoma; Medicine; Tilt (camera); Cancer research; Tumor cells","score_opus":0.010771000269857636,"score_gpt":0.2736602485286825,"score_spread":0.26288924825882487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401502464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917191,0.0017456467,0.0018984576,0.0011865218,0.00007608038,0.000076344215,0.00013074958,0.00011618299,0.0030507892],"genre_scores_gemma":[0.9978472,0.0003926342,0.0006276901,0.0002427546,0.000051366376,0.000011910981,0.00008317533,0.00001168915,0.0007316125],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9998981,0.000011452995,0.000009347921,0.000028346894,0.000015168298,0.00003766792],"domain_scores_gemma":[0.9998124,0.00003881763,0.000024213485,0.000017748054,0.000011397374,0.00009541395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015737653,0.00050346367,0.000667304,0.00034193535,0.0006634456,0.00036096442,0.00031527635,0.0015759959,0.00083285564],"category_scores_gemma":[0.00047316554,0.00026348187,0.000470692,0.00021019933,0.00036946387,0.00029039415,0.00029718594,0.0010192868,0.00029650473],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010888944,0.00029567478,0.023628186,0.00012042254,0.000051136252,0.9135755,0.0003727131,0.0004895615,0.043719713,0.0002806265,0.00057754247,0.015800098],"study_design_scores_gemma":[0.00013281348,0.002770647,0.03093535,0.000024320592,0.00009877336,0.94724464,0.0001348696,0.0022980983,0.013847502,0.00019431504,0.002289439,0.000029261491],"about_ca_topic_score_codex":0.00095074356,"about_ca_topic_score_gemma":0.0013428938,"teacher_disagreement_score":0.0015759959,"about_ca_system_score_codex":0.0005285416,"about_ca_system_score_gemma":0.00028933128,"threshold_uncertainty_score":0.0038349032},"labels":[],"label_agreement":null},{"id":"W4405374307","doi":"10.1016/j.iotech.2024.100796","title":"168TiP A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Institut National Du Cancer; Eisai; Fondation ARC pour la Recherche sur le Cancer; Seagen; Astellas Pharma; NuCana; Sanofi; Exelixis; BeiGene; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Conjugate; Antibody-drug conjugate; Antibody; Medicine; Drug; Cancer research; Monoclonal antibody; Pharmacology; Immunology; Mathematics","score_opus":0.007515845738382482,"score_gpt":0.342843778635392,"score_spread":0.3353279328970095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98893166,0.0017581204,0.00080420956,0.0007985807,0.00021806025,0.0014531064,0.0013634954,0.00022363965,0.004449042],"genre_scores_gemma":[0.9840443,0.0014736603,0.0019166651,0.0008602854,0.000096145224,0.0014462594,0.0030984974,0.000047976046,0.007016197],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99983454,0.00004554596,0.000007944807,0.000028814346,0.000022611528,0.000060471724],"domain_scores_gemma":[0.9997905,0.000028878138,0.000023807645,0.000024456655,0.00001680389,0.000115490184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044050065,0.00083253783,0.0009925081,0.00034015748,0.00025773473,0.0007099393,0.0004917659,0.0008629145,0.005243259],"category_scores_gemma":[0.0003724207,0.00038861306,0.0008744631,0.0002838352,0.00053781515,0.00050079153,0.00023452437,0.0033434965,0.0016050279],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.348612,0.09318656,0.0058244853,0.001196142,0.0012476472,0.000849777,0.00048724603,0.0063357097,0.23473425,0.0011347764,0.02099846,0.28539294],"study_design_scores_gemma":[0.35900036,0.5868213,0.011236126,0.000052309064,0.00051530387,0.0007283782,0.00010008149,0.0029563233,0.026563386,0.0004035508,0.011573614,0.000049196926],"about_ca_topic_score_codex":0.0012397139,"about_ca_topic_score_gemma":0.0020694123,"teacher_disagreement_score":0.005243259,"about_ca_system_score_codex":0.0005883814,"about_ca_system_score_gemma":0.0009324507,"threshold_uncertainty_score":0.017540514},"labels":[],"label_agreement":null},{"id":"W4405374417","doi":"10.1016/j.iotech.2024.100929","title":"176MO ORCA-010 oncolytic therapy: Inducing tumor-specific immune responses and activation of tumor microenvironment in treatment-naïve prostate cancer","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Oakville-Trafalgar Memorial Hospital; Joseph Brant Hospital; The Scarborough Hospital; Brampton Civic Hospital","funders":"Novo Nordisk; National Institute for Health and Care Research; H. Lundbeck A/S; Cancer Research UK; Gordon and Rose McAlpine Foundation for Neuroscience Research; Francis Crick Institute","keywords":"Prostate cancer; Oncolytic virus; Immune system; Tumor microenvironment; Cancer; Medicine; Cancer research; Oncology; Immune escape; Internal medicine; Immunology","score_opus":0.014793106493606751,"score_gpt":0.3085348285810627,"score_spread":0.2937417220874559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99837935,0.00035645103,0.00016562433,0.000025985575,0.000013914278,0.000023429646,0.00007350965,0.000018144836,0.0009435829],"genre_scores_gemma":[0.99874336,0.00010422731,0.00015004582,0.000014116237,0.000004279706,0.000017313365,0.00012102762,0.0000027139513,0.00084293354],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9999063,0.000018566388,0.0000038628878,0.000019054281,0.000020130343,0.00003212671],"domain_scores_gemma":[0.9999702,0.000005116383,0.000004768279,0.0000046427213,0.0000020558264,0.000013290835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009829951,0.00013662457,0.0001644744,0.00009869315,0.00012753083,0.00017748366,0.00012781195,0.00012230164,0.0017801226],"category_scores_gemma":[0.00009967726,0.00007327538,0.000099851735,0.00007798213,0.00012087546,0.00008351029,0.00009162339,0.000354951,0.0001928526],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020625256,0.0010352156,0.0040888805,0.00007285621,0.000033171375,0.00028118707,0.0000961856,0.00047358032,0.9730347,0.00019034256,0.000558613,0.018072732],"study_design_scores_gemma":[0.00059634546,0.032050613,0.104285456,0.000014008072,0.00013566043,0.0031501171,0.0001230788,0.004282368,0.84608024,0.00015374144,0.0091099385,0.00001844082],"about_ca_topic_score_codex":0.0010048504,"about_ca_topic_score_gemma":0.0018519908,"teacher_disagreement_score":0.0017801226,"about_ca_system_score_codex":0.00019873561,"about_ca_system_score_gemma":0.00023776219,"threshold_uncertainty_score":0.0059551},"labels":[],"label_agreement":null},{"id":"W4405374502","doi":"10.1016/j.iotech.2024.101027","title":"LBA3 Perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) in early-stage non-small-cell lung cancer (NSCLC): A 4-year update of KEYNOTE-671","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Chugai Pharmaceutical; EMD Serono; Berlin Institute of Health; Sun Pharma; Teijin Pharma; Medizinische Universität Innsbruck; Freie Universität Berlin; Hôpitaux Universitaires de Genève; Humboldt-Universität zu Berlin; Astellas Pharma; Eisai; Daiichi-Sankyo; Sanofi; Sungkyunkwan University; BeiGene; Mirati Therapeutics; University of Queensland; Helsinn; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Pfizer; Incyte; Universität Innsbruck; Merck KGaA; Taiho Pharmaceutical; Revolution Medicines; Regeneron Pharmaceuticals; Japan Surgical Society; Yuhan; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Amgen; Celgene; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Oncology; Stage (stratigraphy); Perioperative; Chemotherapy; Lung cancer; Internal medicine; Cancer; Radiology; Immunotherapy; Biology","score_opus":0.008401937325614091,"score_gpt":0.2975276717874244,"score_spread":0.2891257344618103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374502","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054150773,0.9750404,0.00092815346,0.0066479505,0.0032411206,0.00010913549,0.0006602393,0.000085612024,0.007872289],"genre_scores_gemma":[0.030095529,0.9433768,0.0032843451,0.013269075,0.0036767279,0.00022545253,0.0021022325,0.000061643754,0.003908273],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993716,0.00013975041,0.00014852142,0.00006242382,0.0001852745,0.000092478236],"domain_scores_gemma":[0.9979778,0.00093524635,0.0004028383,0.000060434017,0.00047029246,0.0001534465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027372271,0.00054623117,0.0015035319,0.0010788286,0.00022860889,0.001318948,0.0010344913,0.0009670343,0.0038348963],"category_scores_gemma":[0.003575833,0.0002924694,0.0014595323,0.0010421919,0.0003187818,0.0014908769,0.00074134377,0.0030036515,0.0014514385],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014300626,0.00013159576,0.00089538796,0.005622956,0.00038448066,0.000110337234,0.000043466207,0.00033527132,0.0019764001,0.0008640785,0.0423771,0.94582886],"study_design_scores_gemma":[0.0020187197,0.0025126727,0.008560107,0.011389348,0.0029171277,0.0013846745,0.00008400313,0.0007298266,0.0028405495,0.0018990665,0.9655876,0.0000761807],"about_ca_topic_score_codex":0.0012816675,"about_ca_topic_score_gemma":0.0051361234,"teacher_disagreement_score":0.0038348963,"about_ca_system_score_codex":0.0013470786,"about_ca_system_score_gemma":0.0017121296,"threshold_uncertainty_score":0.014476001},"labels":[],"label_agreement":null},{"id":"W4405374515","doi":"10.1016/j.iotech.2024.100846","title":"103P Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Esophageal squamous cell carcinoma; Medicine; Chemoradiotherapy; Oncology; Basal cell; Multicenter study; Internal medicine; Carcinoma; Radiation therapy; Randomized controlled trial","score_opus":0.013252142648490887,"score_gpt":0.3187447232035502,"score_spread":0.3054925805550593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81061953,0.17510954,0.0014250026,0.00057920365,0.00041495773,0.0062805745,0.0031274552,0.00006946024,0.002374281],"genre_scores_gemma":[0.9723522,0.018854722,0.0018854885,0.0009510656,0.00028435604,0.0033328063,0.0016560681,0.000019381072,0.0006639575],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.994027,0.0032546835,0.0010419408,0.00084204064,0.0005733771,0.0002609192],"domain_scores_gemma":[0.99388653,0.0019342942,0.0025982398,0.00052094326,0.0006404195,0.00041952802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008706942,0.0013841182,0.004236211,0.0010858,0.0006325548,0.002035554,0.0009542811,0.0020681196,0.004303317],"category_scores_gemma":[0.008670549,0.0009570773,0.009419159,0.0026093135,0.0007901295,0.0016469996,0.0009019704,0.0015349267,0.0009283774],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56114614,0.009741317,0.08552757,0.05896864,0.23235558,0.00068493007,0.00047788245,0.00085826934,0.0031730118,0.00025535162,0.001986476,0.04482485],"study_design_scores_gemma":[0.26961973,0.12939295,0.1696646,0.008245338,0.4080402,0.0013320339,0.00077504775,0.0011545556,0.0015766404,0.00048454787,0.009462917,0.00025145948],"about_ca_topic_score_codex":0.0012108041,"about_ca_topic_score_gemma":0.0022349483,"teacher_disagreement_score":0.008706942,"about_ca_system_score_codex":0.0011873607,"about_ca_system_score_gemma":0.0014188152,"threshold_uncertainty_score":0.04604727},"labels":[],"label_agreement":null},{"id":"W4405374533","doi":"10.1016/j.iotech.2024.100886","title":"2O TILs and PD-L1 early dynamics in the randomized Neo-CheckRay phase II trial evaluating neo-adjuvant immuno-radiation and adenosine pathway blockade for early-stage, high risk ER+/HER2- breast cancer (BC)","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Japanese Respiratory Society; Japan Agency for Medical Research and Development","keywords":"Adenosine; Adjuvant; Blockade; Oncology; Stage (stratigraphy); Medicine; Internal medicine; Breast cancer; Randomized controlled trial; Receptor; Biology; Cancer","score_opus":0.014716830822621232,"score_gpt":0.34418831218317414,"score_spread":0.32947148136055293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937657,0.0020026343,0.00025117307,0.00055338396,0.00015960143,0.0005272433,0.0007420071,0.00006708909,0.0019311231],"genre_scores_gemma":[0.99298626,0.0004798821,0.00056738715,0.00075586716,0.0000951246,0.000760279,0.0014055454,0.000016148933,0.0029333935],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997825,0.0000919526,0.000010283947,0.000047606896,0.000021559646,0.000046184847],"domain_scores_gemma":[0.9996113,0.000087291795,0.000084848354,0.000031567273,0.000027354181,0.00015765043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006900099,0.00046939915,0.0009818691,0.00018278442,0.00022485993,0.00093400414,0.0004042047,0.00075282605,0.005655898],"category_scores_gemma":[0.0008650804,0.00022316386,0.00069937756,0.00015333267,0.00036043624,0.0005071435,0.00033433977,0.0017653392,0.00055957865],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89955765,0.009143846,0.0071578594,0.00042693273,0.000693323,0.00004490071,0.00007636149,0.0010065496,0.009483979,0.00026230558,0.0033191768,0.068827145],"study_design_scores_gemma":[0.6445383,0.30240232,0.036051918,0.00013382873,0.0013431432,0.00018951403,0.00010637071,0.0031112162,0.004641319,0.0010219888,0.0064243516,0.00003571014],"about_ca_topic_score_codex":0.0005783235,"about_ca_topic_score_gemma":0.0014767211,"teacher_disagreement_score":0.005655898,"about_ca_system_score_codex":0.00061926706,"about_ca_system_score_gemma":0.0005897122,"threshold_uncertainty_score":0.018920839},"labels":[],"label_agreement":null},{"id":"W4405374727","doi":"10.1016/j.iotech.2024.100823","title":"80P Tumor markers evolution in pts treated with TCE and association with radiologic response","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Loxo Oncology; Chugai Pharmaceutical; Novartis Pharma; Genentech; PharmaMar; Basilea Pharmaceutica; Astellas Pharma; Eisai; Eisai Canada; BeiGene; Relay Therapeutics; Seagen; Agios Pharmaceuticals; Les Laboratories Pierre Fabre; Pfizer; Incyte; Boston Pharmaceuticals; Merck KGaA; Taiho Pharmaceutical; Daiichi Sankyo Europe; Servier; Foghorn Therapeutics; Gilead Sciences; Bayer HealthCare; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Celgene; Institut National Du Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Association (psychology); Internal medicine; Medicine; Oncology; Psychology; Psychotherapist","score_opus":0.0072704661076379625,"score_gpt":0.27449455691534014,"score_spread":0.26722409080770215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99792236,0.0004699897,0.00007882373,0.00006518509,0.000007665097,0.0000056203316,0.00015539094,0.0000066875236,0.0012883005],"genre_scores_gemma":[0.9993218,0.00007431032,0.00002338385,0.00003051845,0.000011523306,0.0000040173345,0.00016185868,0.000001889647,0.00037058268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998338,0.00003069885,0.000015416079,0.000035973455,0.000031393305,0.000052760894],"domain_scores_gemma":[0.9993979,0.00018124699,0.0002265069,0.000023819368,0.00005565988,0.000114901246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019092001,0.00013973677,0.00027056297,0.00044032073,0.0002016755,0.0004679876,0.00013312887,0.00039553334,0.0014607399],"category_scores_gemma":[0.001563767,0.000090333604,0.00024174507,0.00042849447,0.00018173596,0.000300879,0.00018986255,0.0004345365,0.00023898084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027278413,0.00014865721,0.9839054,0.000021804952,0.00009314166,0.00085612026,0.00009280384,0.00025335312,0.0040137456,0.000056310495,0.00024647845,0.007584368],"study_design_scores_gemma":[0.000015968306,0.0006931029,0.9955715,0.000006634683,0.00007704684,0.001614456,0.00013249942,0.0004767801,0.00069627835,0.000064347856,0.00064590987,0.0000055471605],"about_ca_topic_score_codex":0.0012651676,"about_ca_topic_score_gemma":0.0007634549,"teacher_disagreement_score":0.0014607399,"about_ca_system_score_codex":0.00030278714,"about_ca_system_score_gemma":0.0002008262,"threshold_uncertainty_score":0.004886627},"labels":[],"label_agreement":null},{"id":"W4405374803","doi":"10.1016/j.iotech.2024.100791","title":"162P EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; AstraZeneca; Genentech; Seagen; Institut Servier; INCLIVA Instituto de Investigación Sanitaria; Menarini Group; EMD Serono; Deutschen Konsortium für Translationale Krebsforschung; Sociedad Española de Oncología Médica; PharmaMar; Novartis Farmacéutica; Daiichi Sankyo Europe; European Society for Medical Oncology; Grifols; Fundación Científica Asociación Española Contra el Cáncer; Regeneron Pharmaceuticals; Natera; BeiGene; Les Laboratories Pierre Fabre; Exelixis; Revolution Medicines; Cancer Research UK; Ribon Therapeutics; Takeda Pharmaceuticals International; Array BioPharma; Gilead Sciences; Taiho Pharmaceutical; F. Hoffmann-La Roche; HORIZON EUROPE Framework Programme; Servier; Astellas Pharma; Samsung; Eisai; FibroGen; Bristol-Myers Squibb; Eli Lilly and Company; Institut National Du Cancer; Oncode Institute; American Society of Clinical Oncology; Foundation Medicine; Sierra Oncology; European Association for Cancer Research; Sanofi; Amgen; Pfizer; Celgene","keywords":"Bevacizumab; Nivolumab; Colorectal cancer; Medicine; Oncology; Internal medicine; Metastatic melanoma; Cancer research; Chemotherapy; Immunotherapy; Cancer","score_opus":0.008630389719972233,"score_gpt":0.2672043473917885,"score_spread":0.2585739576718163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954596,0.0026810893,0.00008095397,0.00020069252,0.0000834859,0.000060458908,0.00011972405,0.000008097578,0.0013057872],"genre_scores_gemma":[0.9978865,0.00091717456,0.00015015033,0.0001412237,0.000050030754,0.000040694424,0.00017022407,0.0000016515888,0.00064237823],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998679,0.000049035938,0.000010386082,0.000025992224,0.000013902157,0.00003274501],"domain_scores_gemma":[0.9998267,0.000041534615,0.000033724795,0.00000613019,0.000009430768,0.00008252216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003947846,0.0002297011,0.00057698885,0.00012346284,0.00014762703,0.00030662728,0.00012339986,0.00032102127,0.0015669082],"category_scores_gemma":[0.00066120166,0.00013556835,0.00046983495,0.00019483134,0.00014341595,0.00034005241,0.00016450058,0.0006619078,0.0001896326],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6073079,0.006694918,0.15496103,0.00090123905,0.0014173845,0.00083114137,0.00020000136,0.0016963967,0.016267251,0.00028006049,0.0032914877,0.2061512],"study_design_scores_gemma":[0.05777522,0.34291446,0.5718543,0.00033395158,0.003385122,0.0015777192,0.0004180889,0.0035007424,0.0041696224,0.0005625186,0.013456521,0.00005171862],"about_ca_topic_score_codex":0.0010036258,"about_ca_topic_score_gemma":0.0031574636,"teacher_disagreement_score":0.0015669082,"about_ca_system_score_codex":0.00032151042,"about_ca_system_score_gemma":0.0005084988,"threshold_uncertainty_score":0.005241871},"labels":[],"label_agreement":null},{"id":"W4405374842","doi":"10.1016/j.iotech.2024.100889","title":"5MO Novel radiologic phenotypes of chaotic tumor angiogenesis associated with poor ICI outcomes in NSCLC","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Syöpäsäätiö; Helsingin Yliopisto; Jane ja Aatos Erkon Säätiö; Ida Montinin Säätiö","keywords":"Angiogenesis; Phenotype; Chaotic; Medicine; Oncology; Internal medicine; Cancer research; Computer science; Biology; Genetics; Gene; Artificial intelligence","score_opus":0.018442608517930545,"score_gpt":0.27402059865668604,"score_spread":0.2555779901387555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995175,0.00069460017,0.0009840442,0.0001979183,0.00001541959,0.00001868778,0.0003266714,0.000030087995,0.0025576358],"genre_scores_gemma":[0.99890625,0.000116700336,0.00036039442,0.000031948824,0.000019338451,0.0000109831,0.00020774128,0.0000038810954,0.00034287444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999037,0.000018770974,0.000008165267,0.00002289593,0.000017914634,0.000028534121],"domain_scores_gemma":[0.99956614,0.00005683938,0.00022196947,0.00002240032,0.00006098587,0.000071610644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002898893,0.0002797305,0.00014753245,0.0008139469,0.00021870807,0.0005892161,0.00019062823,0.00038767434,0.002233714],"category_scores_gemma":[0.0006743823,0.000117167,0.00023740747,0.00038268662,0.00027106906,0.00028226434,0.00034499244,0.00035938187,0.00024343538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014183524,0.000117022384,0.8785847,0.00011608536,0.00011954321,0.0026516512,0.0001602719,0.0006212666,0.08779264,0.0011488298,0.0010991502,0.02617049],"study_design_scores_gemma":[0.000032961336,0.00033221758,0.9771593,0.00002297016,0.00009787063,0.005516239,0.00019850668,0.0023621693,0.0111527415,0.0008963783,0.0022148304,0.000013778529],"about_ca_topic_score_codex":0.0008293734,"about_ca_topic_score_gemma":0.00081501756,"teacher_disagreement_score":0.002233714,"about_ca_system_score_codex":0.00031038641,"about_ca_system_score_gemma":0.00018623588,"threshold_uncertainty_score":0.007472515},"labels":[],"label_agreement":null},{"id":"W4405374985","doi":"10.1016/j.iotech.2024.100845","title":"102P A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lenvatinib; Hepatocellular carcinoma; Medicine; Oncology; Internal medicine; Second line; Line (geometry); First line; Sorafenib","score_opus":0.035857103639493786,"score_gpt":0.2980887263409522,"score_spread":0.2622316227014584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374985","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28688538,0.69296473,0.0015344027,0.0016028858,0.00074036786,0.0030556393,0.009244036,0.00007692945,0.003895596],"genre_scores_gemma":[0.94675213,0.046420783,0.0013155341,0.00094678946,0.0003273381,0.00146398,0.0021392268,0.00002348996,0.0006108296],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.9860486,0.007593296,0.0034247052,0.001400814,0.0011783747,0.0003542123],"domain_scores_gemma":[0.9629764,0.021697592,0.010955938,0.0013042786,0.0024100214,0.0006556943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013777523,0.0010781377,0.0059560384,0.002700443,0.00047537967,0.0022950908,0.0010220454,0.0021424335,0.0067052576],"category_scores_gemma":[0.041180283,0.0007225588,0.01770582,0.0038068786,0.00073949614,0.0016596168,0.0011064718,0.0019202589,0.0006352427],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1379711,0.0009853693,0.044949524,0.23120329,0.5444107,0.0006760793,0.0003685135,0.0008716004,0.0010166803,0.00043470852,0.00207144,0.035040967],"study_design_scores_gemma":[0.05439051,0.0168176,0.085780516,0.033329386,0.7956727,0.00091216003,0.0004524764,0.0009841886,0.0007580036,0.00055363146,0.010189447,0.0001594019],"about_ca_topic_score_codex":0.0023081747,"about_ca_topic_score_gemma":0.0031400197,"teacher_disagreement_score":0.013777523,"about_ca_system_score_codex":0.0017960253,"about_ca_system_score_gemma":0.002167232,"threshold_uncertainty_score":0.0728634},"labels":[],"label_agreement":null},{"id":"W4405374998","doi":"10.1016/j.iotech.2024.100749","title":"120MO Inupadenant combined with chemotherapy in patients with non-squamous NSCLC progressing on or after immune checkpoint inhibitor therapy: Results from dose-finding part of the A2A-005 trial","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; Brampton Civic Hospital","funders":"","keywords":"Medicine; Oncology; Chemotherapy; Internal medicine; Immune checkpoint; Immune system; Immunotherapy; Immunology; Cancer","score_opus":0.012900915253423132,"score_gpt":0.2756339601567856,"score_spread":0.26273304490336247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405374998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948932,0.002276967,0.00012470224,0.00023020993,0.00007409871,0.00042331248,0.00043047246,0.00003374404,0.001513377],"genre_scores_gemma":[0.99422187,0.0016347935,0.0002732357,0.0004550661,0.00010018131,0.00044717814,0.0012704361,0.000010795545,0.0015863476],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99974567,0.00012825422,0.000014571918,0.000041941454,0.000021826838,0.000047793743],"domain_scores_gemma":[0.9997855,0.000033901662,0.000048792976,0.000018746414,0.000011968915,0.00010126766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075839134,0.00067559973,0.0011510882,0.0002104823,0.00018862274,0.0008164323,0.00040118283,0.000605406,0.0024194806],"category_scores_gemma":[0.000392437,0.00020276006,0.0011892885,0.00025428945,0.00035496047,0.0005108906,0.00024191341,0.0015439271,0.00041330623],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80523044,0.018532157,0.014609287,0.0014468369,0.0031850587,0.0001805383,0.00023273948,0.0022810963,0.02447647,0.0003520979,0.0035709091,0.12590238],"study_design_scores_gemma":[0.5381893,0.3998522,0.04765298,0.00017751378,0.0021195563,0.00029095743,0.00012105008,0.0017312071,0.0039130542,0.00039346254,0.0055243727,0.000034362933],"about_ca_topic_score_codex":0.00064880936,"about_ca_topic_score_gemma":0.0017413824,"teacher_disagreement_score":0.0024194806,"about_ca_system_score_codex":0.0006022121,"about_ca_system_score_gemma":0.000619167,"threshold_uncertainty_score":0.008093953},"labels":[],"label_agreement":null},{"id":"W4405375041","doi":"10.1016/j.iotech.2024.100746","title":"117O Stereotactic body radiotherapy (SBRT) with pembrolizumab (pembro) for unresected stage I/II non-small cell lung cancer (NSCLC): The randomized, double-blind, phase III KEYNOTE-867 study","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Stage (stratigraphy); Oncology; Medical physics; Internal medicine; Cancer; Immunotherapy; Biology","score_opus":0.017121381715622202,"score_gpt":0.3587965159867576,"score_spread":0.3416751342711354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405375041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859611,0.0038295684,0.00091222225,0.0004523642,0.00048813657,0.003491119,0.00132577,0.00015554894,0.0033842444],"genre_scores_gemma":[0.9817343,0.003961542,0.0016953665,0.0012020201,0.0003764976,0.0037907218,0.0019791077,0.000048103113,0.005212345],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99945444,0.0002752892,0.00002978933,0.00008441006,0.000045921057,0.000110160785],"domain_scores_gemma":[0.99959844,0.000086334774,0.0000819579,0.000041251915,0.000031276315,0.00016075833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012870536,0.0015188863,0.0026130378,0.00044574006,0.00043237588,0.0009461566,0.0007268192,0.0014295902,0.0061529423],"category_scores_gemma":[0.0007495861,0.0007270101,0.0017746042,0.00049194734,0.0011236415,0.00083816267,0.00045158,0.002854526,0.0015870581],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97010046,0.008177365,0.0006173941,0.0005065232,0.00093484676,0.00002118925,0.000028533355,0.00031202385,0.004420928,0.00011389758,0.0008159895,0.013950925],"study_design_scores_gemma":[0.9238359,0.07288223,0.0012980102,0.000019751516,0.00046682847,0.000024897397,0.000013404548,0.00020799847,0.0006108389,0.00007654631,0.00055437465,0.000009105487],"about_ca_topic_score_codex":0.0012759014,"about_ca_topic_score_gemma":0.0021026835,"teacher_disagreement_score":0.0061529423,"about_ca_system_score_codex":0.00059997174,"about_ca_system_score_gemma":0.0013123432,"threshold_uncertainty_score":0.02058357},"labels":[],"label_agreement":null},{"id":"W4405375144","doi":"10.1016/j.iotech.2024.100750","title":"121MO Anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: Final analysis from the randomized part 2 of the phase I/II CA027-002 study","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; PharmaMar; European Society for Medical Oncology","keywords":"Nivolumab; Ipilimumab; Medicine; Metastatic melanoma; Internal medicine; Melanoma; Oncology; Cancer research; Immunotherapy; Cancer","score_opus":0.008657859952414042,"score_gpt":0.2774406519264998,"score_spread":0.2687827919740858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405375144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99655664,0.0018066874,0.0001441797,0.0001861067,0.000043574124,0.00033400857,0.00024418463,0.000025924855,0.00065871875],"genre_scores_gemma":[0.99671376,0.0009977483,0.00040770057,0.00018748234,0.000068785404,0.00029158825,0.0004967999,0.0000059267345,0.00083022995],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99968505,0.00018285036,0.000015696765,0.000037003654,0.000034118406,0.00004532568],"domain_scores_gemma":[0.9997094,0.000065518405,0.000068976224,0.000021180955,0.000020097186,0.00011472713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010177308,0.00050886127,0.00093023403,0.00024034939,0.00018476624,0.00050188706,0.00032259207,0.00044116296,0.001985405],"category_scores_gemma":[0.00064973073,0.00030897636,0.00082497526,0.00024906956,0.00027568964,0.00033526734,0.00022598014,0.0011134136,0.0003939196],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7574698,0.01671321,0.021296456,0.00094622414,0.003184005,0.000177556,0.00016647248,0.002097182,0.03708604,0.00014476877,0.0029036682,0.15781473],"study_design_scores_gemma":[0.43362954,0.47303778,0.07618814,0.0000819798,0.0025135663,0.00030605186,0.00007179294,0.0022979397,0.007187608,0.00017569165,0.0044780476,0.000031886197],"about_ca_topic_score_codex":0.0006287582,"about_ca_topic_score_gemma":0.0021332675,"teacher_disagreement_score":0.001985405,"about_ca_system_score_codex":0.0004716797,"about_ca_system_score_gemma":0.0005680472,"threshold_uncertainty_score":0.006641805},"labels":[],"label_agreement":null},{"id":"W4407087806","doi":"10.1016/j.iotech.2025.101042","title":"Challenges and opportunities of predicting overall survival benefit from improvements to recurrence-free survival in stage II/III melanoma: a correlation meta-analysis","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Celgene; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Stage (stratigraphy); Meta-analysis; Overall survival; Correlation; Melanoma; Oncology; Internal medicine; Survival analysis; Medicine; Biology; Mathematics; Cancer research","score_opus":0.07049526614308026,"score_gpt":0.3109782898953646,"score_spread":0.2404830237522843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407087806","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008812406,0.96281916,0.020093905,0.0050312234,0.0006381521,0.00044936448,0.0008041605,0.00015484574,0.0011968052],"genre_scores_gemma":[0.622089,0.32580572,0.037168395,0.008419817,0.0019810644,0.0022392382,0.001316271,0.00026388033,0.00071659684],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9104933,0.07402268,0.007667121,0.004191295,0.0030584089,0.0005671287],"domain_scores_gemma":[0.7430065,0.22728705,0.014484096,0.009270404,0.0052314387,0.0007204924],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.1309706,0.003126578,0.011284078,0.0058618383,0.00046028921,0.005729032,0.002348405,0.0016033341,0.0025442445],"category_scores_gemma":[0.22827764,0.0014677487,0.0350067,0.0049928073,0.001161307,0.0027421217,0.0023677882,0.003500603,0.0003784257],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015965956,0.000030170915,0.018837117,0.068462215,0.857779,0.00014186744,0.00011240451,0.0047119316,0.00024002278,0.0019774386,0.0015891612,0.04452205],"study_design_scores_gemma":[0.0006596084,0.00046039547,0.009553472,0.018730052,0.94840384,0.00018821763,0.000083004146,0.004980149,0.00032363116,0.010271901,0.0062808204,0.00006490685],"about_ca_topic_score_codex":0.0034674432,"about_ca_topic_score_gemma":0.004842442,"teacher_disagreement_score":0.8690294,"about_ca_system_score_codex":0.0018328372,"about_ca_system_score_gemma":0.0038325253,"threshold_uncertainty_score":0.692647},"labels":[],"label_agreement":null},{"id":"W7117291323","doi":"10.1016/j.iotech.2025.101225","title":"141P Clinical study of camrelizumab combined with SOX in adjuvant therapy for gastric or gastroesophageal junction adenocarcinoma: Interim report","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Jonsson Comprehensive Cancer Center; University of Colorado Denver; University of Pittsburgh; Medical Center, University of Pittsburgh; Vanderbilt University Medical Center; McGill University Health Centre; McGill University; Northwestern University; University of Texas MD Anderson Cancer Center; School of Medicine, Stanford University; Vanderbilt University; Moffitt Cancer Center; Ohio State University","keywords":"Clinical study; Gastroesophageal Junction; Adjuvant therapy; Clinical trial; Adjuvant; Interim; Interim analysis","score_opus":0.03616686054081508,"score_gpt":0.384055794376691,"score_spread":0.34788893383587594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117291323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89130634,0.036607027,0.002394308,0.0077492986,0.0020781546,0.009855422,0.013625174,0.0002675453,0.03611667],"genre_scores_gemma":[0.9459232,0.013522291,0.003048116,0.0060432185,0.0015135339,0.0050073555,0.013124009,0.000053126078,0.011765221],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994585,0.00022824827,0.00005251052,0.0000701391,0.00009531769,0.00009527407],"domain_scores_gemma":[0.99928623,0.00014120551,0.00013153342,0.00007091245,0.000102965074,0.0002672061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017819343,0.0005135106,0.001036566,0.0002074457,0.00028314302,0.0010311061,0.00037928965,0.0010374513,0.0073547955],"category_scores_gemma":[0.0015644453,0.00019765581,0.0014824028,0.00038216964,0.000333961,0.00059331045,0.00034196256,0.001974679,0.0017524777],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51911366,0.018393353,0.024898494,0.0046771336,0.0052630976,0.0017536925,0.00026841526,0.0015566992,0.019698417,0.0009477656,0.03584139,0.36758783],"study_design_scores_gemma":[0.3296034,0.50904036,0.06242285,0.000868861,0.0043615308,0.0019595907,0.00013647799,0.0013661699,0.007970582,0.00092954276,0.08127813,0.00006252715],"about_ca_topic_score_codex":0.00045299547,"about_ca_topic_score_gemma":0.00085991074,"teacher_disagreement_score":0.0073547955,"about_ca_system_score_codex":0.0006027176,"about_ca_system_score_gemma":0.0012735395,"threshold_uncertainty_score":0.02460426},"labels":[],"label_agreement":null},{"id":"W7117293508","doi":"10.1016/j.iotech.2025.101116","title":"33P High-dimensional spatial profiling of the tumor immune microenvironment (TIME) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) reveals predictive biomarkers of immunotherapy","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Single-cell and spatial transcriptomics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Head and neck squamous-cell carcinoma; Immunotherapy; Profiling (computer programming); Tumor microenvironment; Immune system; Head and neck; Basal cell; Head and neck cancer","score_opus":0.00478656131430803,"score_gpt":0.22246178456069884,"score_spread":0.21767522324639083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117293508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849841,0.0013801376,0.011015171,0.00013005309,0.000012117987,0.000013989934,0.0010877827,0.0000825283,0.0012940568],"genre_scores_gemma":[0.9894386,0.0011317823,0.007262528,0.00004801579,0.0000058745377,0.00003489597,0.00070468715,0.00003149433,0.0013421354],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99996424,0.000004292422,0.000001534746,0.000009119005,0.0000118844,0.000008869228],"domain_scores_gemma":[0.9999603,0.000012563589,0.000011251118,0.0000035283151,0.000006616733,0.000005720247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000084087886,0.000095132826,0.00009227337,0.00021609031,0.00014115176,0.00023040718,0.000093902476,0.0001717475,0.00064595207],"category_scores_gemma":[0.00010634041,0.00013935023,0.00010080028,0.00024431944,0.00017381442,0.00014893276,0.00013373909,0.00028807865,0.00019794701],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000088910696,0.000005443159,0.0010541369,0.000025042687,0.0000042871834,0.00007171638,0.000022558275,0.00048584052,0.99608433,0.00013339787,0.00007419365,0.00195009],"study_design_scores_gemma":[0.000013734717,0.00016004803,0.09025331,0.000010933647,0.000037993974,0.0008362525,0.00029605333,0.009659724,0.89480174,0.0006130636,0.003299422,0.000017700546],"about_ca_topic_score_codex":0.0010811286,"about_ca_topic_score_gemma":0.0021843652,"teacher_disagreement_score":0.0010811286,"about_ca_system_score_codex":0.00019201501,"about_ca_system_score_gemma":0.00016674768,"threshold_uncertainty_score":0.0021609664},"labels":[],"label_agreement":null},{"id":"W7117296119","doi":"10.1016/j.iotech.2025.101450","title":"251P Final results of the FAK-PD1 phase I/IIA study of FAK (defactinib) and PD-1 (pembrolizumab) inhibition in advanced solid tumours","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"NIH Clinical Center; University of California, San Diego; Genentech; Sierra Oncology; Ipsen; Servier; Weill Cornell Medical College; National Institute for Health and Care Research; Seagen; Sidney Kimmel Comprehensive Cancer Center; Pfizer; Moderna; NuCana; Incyte; Boston Pharmaceuticals; Cancer Research UK; Verastem Oncology; Amgen; Barbara Ann Karmanos Cancer Institute; BeiGene; Les Laboratories Pierre Fabre; Moffitt Cancer Center; Sanofi; Exelixis; Astellas Pharma; Eisai; Thomas Jefferson University; Johns Hopkins University; Celgene; Institut National Du Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Phase (matter); Cancer; Solid tumor; Cytotoxicity","score_opus":0.02047705227220095,"score_gpt":0.385868474467102,"score_spread":0.36539142219490106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117296119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68633294,0.040109776,0.011434006,0.034479734,0.012740218,0.013011918,0.05784782,0.0012404934,0.14280315],"genre_scores_gemma":[0.72971666,0.016508136,0.013835853,0.020053789,0.003583398,0.004700373,0.06661545,0.0005476069,0.14443876],"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994136,0.00019988086,0.00003129207,0.000064339925,0.00015116735,0.00013966515],"domain_scores_gemma":[0.99944955,0.00008604148,0.000032090087,0.000034875007,0.00011594677,0.00028151635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021257407,0.0011465717,0.00096510054,0.00038217075,0.00058398163,0.0012313648,0.00084117346,0.0017503593,0.006891348],"category_scores_gemma":[0.0007996411,0.00039341522,0.0011779919,0.00017863562,0.00044211288,0.00029409563,0.00045165708,0.0019265659,0.0023021826],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2144213,0.01565322,0.004417522,0.001315639,0.0025051814,0.0025462392,0.00017181836,0.0035314537,0.16289075,0.0014515423,0.3498106,0.24128483],"study_design_scores_gemma":[0.20447423,0.23202184,0.05871495,0.00028525136,0.0034008091,0.0033202365,0.00013442906,0.0040815584,0.15516998,0.0019169993,0.33633628,0.0001433691],"about_ca_topic_score_codex":0.0024271274,"about_ca_topic_score_gemma":0.0043332484,"teacher_disagreement_score":0.006891348,"about_ca_system_score_codex":0.0010228349,"about_ca_system_score_gemma":0.0014526062,"threshold_uncertainty_score":0.023053825},"labels":[],"label_agreement":null},{"id":"W7117298964","doi":"10.1016/j.iotech.2025.101461","title":"262P EGFR mutations (EGFR+) or ALK rearrangements (ALK+) in the BR31 trial of adjuvant durvalumab (D) v placebo (P)","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Cancer Society; Dalhousie University; University of Ottawa","funders":"","keywords":"Durvalumab; Placebo; Adjuvant; Mutation; Clinical trial","score_opus":0.01786102216622019,"score_gpt":0.3937564791857949,"score_spread":0.3758954570195747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117298964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885203,0.0047431616,0.00033286758,0.0011904064,0.00047032235,0.00023370025,0.0005660235,0.00006906875,0.0038741864],"genre_scores_gemma":[0.9939579,0.0011651765,0.00032053053,0.00052834605,0.00014990232,0.0001084032,0.00050323404,0.00001052057,0.003256112],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996294,0.00016524742,0.000014783111,0.00005484944,0.000022035509,0.00011371378],"domain_scores_gemma":[0.99976975,0.000061955325,0.000034100965,0.000022041335,0.000009822689,0.00010240817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008306024,0.00080875534,0.0015169581,0.00014103766,0.00020173204,0.00078806875,0.00044330617,0.00079498073,0.004417596],"category_scores_gemma":[0.00071307906,0.0003380089,0.00083450007,0.00014613809,0.0006157972,0.0007584467,0.00021605137,0.0022043232,0.0006774647],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94018745,0.0026554328,0.0012168842,0.000269739,0.0005604104,0.00008696853,0.000041077266,0.00057256245,0.010363307,0.000582334,0.0026002566,0.040863678],"study_design_scores_gemma":[0.81855214,0.15624027,0.011645936,0.00011516548,0.0010105281,0.0003126891,0.00007887981,0.0020237924,0.003272583,0.0010656151,0.0056446274,0.000037760637],"about_ca_topic_score_codex":0.0010838804,"about_ca_topic_score_gemma":0.003029534,"teacher_disagreement_score":0.004417596,"about_ca_system_score_codex":0.0005694841,"about_ca_system_score_gemma":0.0007318858,"threshold_uncertainty_score":0.014778316},"labels":[],"label_agreement":null},{"id":"W7117304384","doi":"10.1016/j.iotech.2025.101199","title":"114P Exploring the role of FES kinase in natural killer cells to enhance immunotherapy","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Immunotherapy; Kinase; Immune system; Natural killer cell; Cancer immunotherapy; Tyrosine kinase","score_opus":0.006114528020794343,"score_gpt":0.2639369299625833,"score_spread":0.25782240194178896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117304384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91767263,0.04052369,0.014458867,0.0034259062,0.00051305984,0.00040717178,0.0005323177,0.00022509442,0.022241239],"genre_scores_gemma":[0.964068,0.013797293,0.0069933715,0.00036410996,0.00008374433,0.00012819402,0.0004643232,0.00001839124,0.014082542],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999449,0.00000946322,0.0000034122443,0.000007696149,0.00001693507,0.000017488184],"domain_scores_gemma":[0.99996436,0.000008742607,0.000007723907,0.0000025631373,0.000007665116,0.00000891113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020439814,0.00034424043,0.00015534722,0.00015811627,0.00009325551,0.00034477972,0.00023746814,0.00040082788,0.0044952035],"category_scores_gemma":[0.00012256888,0.00006818409,0.00019726514,0.00008660001,0.0002292434,0.00031798138,0.00018542206,0.00050861394,0.00078477844],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080111803,0.00028090941,0.0004951038,0.00046383042,0.000018687286,0.00023072782,0.000030171528,0.0011018217,0.9390634,0.0027744616,0.0014207796,0.05331909],"study_design_scores_gemma":[0.00065234985,0.005730366,0.003432941,0.00013966848,0.00006139342,0.001456387,0.00006597472,0.004964101,0.9061073,0.0020863216,0.07528597,0.00001735932],"about_ca_topic_score_codex":0.00019065439,"about_ca_topic_score_gemma":0.00027947567,"teacher_disagreement_score":0.0044952035,"about_ca_system_score_codex":0.0003747538,"about_ca_system_score_gemma":0.00025668318,"threshold_uncertainty_score":0.015037954},"labels":[],"label_agreement":null},{"id":"W7117306831","doi":"10.1016/j.iotech.2025.101226","title":"142P Infusion time of adjuvant PD-1 therapy in high-risk resectable melanoma: Accounting for distance from clinic, scheduling changes over time, and appropriately adjusting p-values in SWOG S1404","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Merck; Bristol-Myers Squibb","keywords":"Scheduling (production processes); Adjuvant; Adjuvant therapy; Continuous infusion","score_opus":0.010780104697606567,"score_gpt":0.2866931739268872,"score_spread":0.27591306922928066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117306831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710298,0.002172989,0.019818189,0.0010672258,0.00056817674,0.0000486868,0.0018893502,0.0002444919,0.0031610457],"genre_scores_gemma":[0.9940978,0.00010470604,0.0036663807,0.000115271156,0.000058527217,0.000034313183,0.0005429199,0.0001072488,0.001272766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99570197,0.001967219,0.00035492834,0.0011526548,0.00046691397,0.00035625603],"domain_scores_gemma":[0.9825472,0.013212143,0.0018274606,0.0012970865,0.0005174586,0.00059864635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072675343,0.0003961199,0.00080410583,0.00046250326,0.00030057537,0.0011791589,0.0011320269,0.000565339,0.0035916017],"category_scores_gemma":[0.026946023,0.000282358,0.0015083266,0.001076456,0.00028027402,0.0010064155,0.0004987272,0.0016508043,0.00042230595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014404482,0.00037652298,0.788766,0.00027156877,0.0039446815,0.00053337927,0.00026896887,0.031056017,0.0027125156,0.0011242019,0.0060188686,0.1505228],"study_design_scores_gemma":[0.0004916032,0.0024709583,0.73165566,0.00013303277,0.0030645258,0.00092264876,0.0004950759,0.23797572,0.005189328,0.0036124093,0.013921521,0.000067412264],"about_ca_topic_score_codex":0.0070560942,"about_ca_topic_score_gemma":0.0069285817,"teacher_disagreement_score":0.0072675343,"about_ca_system_score_codex":0.0008658115,"about_ca_system_score_gemma":0.0014194903,"threshold_uncertainty_score":0.038434863},"labels":[],"label_agreement":null},{"id":"W7117306841","doi":"10.1016/j.iotech.2025.101399","title":"402P TMEM33 loss enhances CD8+ T cell functionality and tumour control","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"T cell; Cytotoxic T cell; Immune system; T lymphocyte; Cell","score_opus":0.006170921108255087,"score_gpt":0.28137488002997735,"score_spread":0.2752039589217223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117306841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961422,0.00035429682,0.0012126968,0.00014925495,0.000033426262,0.000020065696,0.00024137912,0.00008519406,0.0017615814],"genre_scores_gemma":[0.9963181,0.00013064704,0.0004973994,0.000051712053,0.0000047640715,0.000016692084,0.00024699632,0.000020022191,0.0027135636],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982685,0.00003323356,0.000008925296,0.000023429917,0.000037901256,0.0000697126],"domain_scores_gemma":[0.99993956,0.000014201022,0.000015121898,0.000009351475,0.0000047980698,0.000017033848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001086282,0.00027516368,0.00016612794,0.000116278585,0.00014062942,0.00030391826,0.00015170865,0.00047127344,0.004083157],"category_scores_gemma":[0.00011996247,0.00012137753,0.00016298317,0.000115387666,0.00024888298,0.0002442468,0.00020970947,0.0010073483,0.00085615716],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025526044,0.00005181343,0.00010580085,0.00001948314,0.0000036980032,0.00006685885,0.000013277937,0.00014698535,0.99771154,0.00018579679,0.00012767264,0.0013118528],"study_design_scores_gemma":[0.00004149853,0.00044281734,0.0022877322,0.000004511147,0.000011240966,0.0003682855,0.00004197201,0.0013723626,0.9907267,0.000102726306,0.0045958543,0.0000042462566],"about_ca_topic_score_codex":0.000459873,"about_ca_topic_score_gemma":0.00038529883,"teacher_disagreement_score":0.004083157,"about_ca_system_score_codex":0.00023553993,"about_ca_system_score_gemma":0.00017283372,"threshold_uncertainty_score":0.013659537},"labels":[],"label_agreement":null},{"id":"W7117307022","doi":"10.1016/j.iotech.2025.101348","title":"351P Association of G-coupled protein receptor 65 (GPR65), a novel therapeutic target, with immune cell subsets in metastatic renal cell carcinoma (mRCC)","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Renal cell carcinoma; Immune system; Kidney cancer; Receptor; Cell; Immunotherapy; T cell; Kidney","score_opus":0.009426331137015345,"score_gpt":0.25070166207310923,"score_spread":0.24127533093609388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117307022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939253,0.0029325811,0.0010035118,0.00023342422,0.00007146,0.000018577599,0.000110019784,0.000030140734,0.0016750267],"genre_scores_gemma":[0.99662906,0.0009839864,0.00043970137,0.00011067894,0.000013133056,0.000012740143,0.00014578098,0.0000043905898,0.001660508],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99990046,0.000017300295,0.000004054426,0.000017475337,0.000019002506,0.000041801468],"domain_scores_gemma":[0.99998057,0.0000032059756,0.0000048460383,0.0000019090157,0.000002281622,0.0000071865707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001440817,0.00016782596,0.00020719485,0.00010416166,0.0001590256,0.0002538215,0.00012910631,0.00026902324,0.0020648362],"category_scores_gemma":[0.0001212999,0.00008877632,0.00023946165,0.00011494894,0.00014109214,0.00016461012,0.00026549594,0.0003639792,0.000387168],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009820297,0.00009864671,0.0014289054,0.00016554202,0.00003588414,0.00027022796,0.0000715087,0.00029262863,0.9822467,0.0006038408,0.000629559,0.01317457],"study_design_scores_gemma":[0.00040703383,0.006133383,0.041318037,0.00006829297,0.000308642,0.0036530406,0.00050140504,0.0038064905,0.9049093,0.0009004929,0.037966006,0.000027850696],"about_ca_topic_score_codex":0.00062652637,"about_ca_topic_score_gemma":0.00066001894,"teacher_disagreement_score":0.0020648362,"about_ca_system_score_codex":0.00021603839,"about_ca_system_score_gemma":0.00018990148,"threshold_uncertainty_score":0.0069075227},"labels":[],"label_agreement":null},{"id":"W7117310539","doi":"10.1016/j.iotech.2025.101097","title":"12P Stromal CD73 expression in early-stage high-risk luminal B-like breast cancer: An exploratory analysis from the randomized Neo-CheckRay trial","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Stromal cell; Exploratory analysis; Adenosine; Breast cancer; Immune system; Pathological; Randomized controlled trial; Clinical trial","score_opus":0.006197744301364331,"score_gpt":0.26985468137124136,"score_spread":0.26365693706987703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117310539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749976,0.0010406766,0.00012830179,0.00010395834,0.000015704914,0.00008977963,0.0006086023,0.000006651135,0.0005065078],"genre_scores_gemma":[0.99778914,0.00024473856,0.00021066298,0.00009833226,0.000047815756,0.00010346856,0.0011182504,0.0000031052484,0.00038457313],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9996561,0.00019049704,0.000017708291,0.000053741027,0.00003962282,0.000042393214],"domain_scores_gemma":[0.9993179,0.00024229047,0.00018579412,0.00007686955,0.000050993054,0.00012611433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010297628,0.00035995,0.0006212513,0.00013742014,0.00015354087,0.00050770503,0.00024183569,0.00031469736,0.0018995878],"category_scores_gemma":[0.0009119123,0.00012669897,0.00056997145,0.00025106658,0.00028905144,0.00026987254,0.00023142768,0.00058867637,0.00019284543],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73411494,0.0024325282,0.18864943,0.0006377233,0.0026410208,0.00027810162,0.00009464449,0.00090733805,0.019638019,0.0003918235,0.0022412757,0.04797317],"study_design_scores_gemma":[0.13959795,0.087051705,0.74517816,0.00009779834,0.006525022,0.0011705247,0.00022265055,0.0031147015,0.008869152,0.0010263851,0.0070827943,0.00006316227],"about_ca_topic_score_codex":0.00027235708,"about_ca_topic_score_gemma":0.00072538585,"teacher_disagreement_score":0.0018995878,"about_ca_system_score_codex":0.00028680486,"about_ca_system_score_gemma":0.00027713433,"threshold_uncertainty_score":0.006354809},"labels":[],"label_agreement":null},{"id":"W7117311906","doi":"10.1016/j.iotech.2025.101202","title":"117eP In vitro assessment of an EphA2-targeting CAR-T cell therapy for NSCLC","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"In vitro; Radiation therapy; Cell; Cancer therapy; Cancer; Cell therapy","score_opus":0.016533222373132594,"score_gpt":0.38570954537494284,"score_spread":0.36917632300181025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117311906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98623925,0.0029919553,0.00411347,0.000115551586,0.0000656757,0.000129028,0.00035763916,0.000047459554,0.0059398664],"genre_scores_gemma":[0.98890615,0.0012055972,0.0030624203,0.000050873456,0.000019144305,0.00010577427,0.0006570856,0.000013907843,0.005978932],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995925,0.00014967112,0.00002712597,0.00003262902,0.00012314052,0.00007500406],"domain_scores_gemma":[0.9998853,0.00005062703,0.00000829003,0.000009568812,0.000030160489,0.000016020833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050124165,0.00029606267,0.00033637605,0.00024927175,0.00017529454,0.0004236965,0.00026050664,0.00044662607,0.0026472115],"category_scores_gemma":[0.0002410622,0.00015395679,0.0002515662,0.00023201735,0.00012982466,0.0002242367,0.00015726476,0.00057918427,0.0006580066],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037010328,0.00033931524,0.00021752862,0.00011737599,0.0000206985,0.00010076687,0.00005192112,0.0010863681,0.99208814,0.00019312279,0.00016742482,0.0052472767],"study_design_scores_gemma":[0.00003533664,0.0018404622,0.0009173825,0.0000057041916,0.000035408488,0.000103410355,0.000029906445,0.002763138,0.9925465,0.000023811797,0.0016950235,0.0000038575554],"about_ca_topic_score_codex":0.0019496026,"about_ca_topic_score_gemma":0.0020141245,"teacher_disagreement_score":0.0026472115,"about_ca_system_score_codex":0.00028500202,"about_ca_system_score_gemma":0.00038635908,"threshold_uncertainty_score":0.00885582},"labels":[],"label_agreement":null},{"id":"W7117312005","doi":"10.1016/j.iotech.2025.101572","title":"395P Synthetic IL-12 immunotherapy reverses immune suppression and halts metastasis in pancreatic cancer","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Immunotherapy; Pancreatic cancer; Immune system; Pancreatic ductal adenocarcinoma; Metastasis; Cytokine; Infiltration (HVAC); Tumor microenvironment","score_opus":0.016928231344369164,"score_gpt":0.3463640821661589,"score_spread":0.3294358508217897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117312005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849609,0.0042633126,0.0052476036,0.000565634,0.00021164033,0.00006099149,0.00036185404,0.00035850517,0.003969651],"genre_scores_gemma":[0.99068403,0.0016370816,0.0025287168,0.000107386135,0.00002544403,0.000051253763,0.00036457684,0.00003382111,0.0045676706],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991906,0.000012552687,0.000005006116,0.00001150798,0.000029340787,0.000022551092],"domain_scores_gemma":[0.9999604,0.000007693955,0.0000073305837,0.000005023694,0.0000039698984,0.000015706539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001132995,0.0002394379,0.00021648585,0.00022137439,0.000107909014,0.00021693856,0.0001886747,0.0002644962,0.002049252],"category_scores_gemma":[0.000089118905,0.00009300623,0.00014447985,0.0001406761,0.0002679599,0.00016570475,0.00015423258,0.00090621685,0.0004513502],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007196939,0.00029234964,0.000106111074,0.000113761336,0.000009697899,0.00011987539,0.000028410352,0.0008871291,0.9834012,0.0004772374,0.0005543931,0.01329009],"study_design_scores_gemma":[0.00029468842,0.003280137,0.0011724497,0.000014276705,0.000025777033,0.00044873852,0.000031294643,0.0034427475,0.9785265,0.00022469764,0.012529826,0.0000089299265],"about_ca_topic_score_codex":0.00040586,"about_ca_topic_score_gemma":0.00063749135,"teacher_disagreement_score":0.002049252,"about_ca_system_score_codex":0.00022221052,"about_ca_system_score_gemma":0.00030126018,"threshold_uncertainty_score":0.0068553686},"labels":[],"label_agreement":null},{"id":"W7117315492","doi":"10.1016/j.iotech.2025.101210","title":"126P Neoadjuvant (neoadj) nivolumab (N) + chemotherapy (C) in patients (pts) with resectable NSCLC: Outcomes by subsequent immunotherapy (IO) in CheckMate 816","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College; McGill University Health Centre","funders":"","keywords":"Nivolumab; Chemotherapy; Immunotherapy; Chemoimmunotherapy; Neoadjuvant therapy; MEDLINE","score_opus":0.005142110023032019,"score_gpt":0.27443932435254625,"score_spread":0.26929721432951426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117315492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99807477,0.00071675546,0.000052120384,0.00007577875,0.000032575255,0.000014117042,0.00019467878,0.0000069185753,0.0008323085],"genre_scores_gemma":[0.9985525,0.00022090663,0.000051793835,0.00008970773,0.000024895646,0.000013136686,0.00049436186,0.0000015901174,0.0005511467],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999928,0.000014167554,0.000004062701,0.000021029462,0.000007824179,0.000024920333],"domain_scores_gemma":[0.9998423,0.000029118382,0.000035609388,0.000011183628,0.000008457091,0.000073296935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016423666,0.00017688744,0.00032629297,0.0000999631,0.00014310422,0.0004411949,0.00012985588,0.00024490227,0.0015658849],"category_scores_gemma":[0.0004005452,0.00008630339,0.0005184008,0.00014369671,0.00015447263,0.0003046592,0.00022176014,0.0004972481,0.00025070275],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2157743,0.0028600863,0.62288624,0.00031730387,0.00076766085,0.0006248847,0.0001718219,0.00198179,0.012811253,0.00027025142,0.0036851114,0.13784923],"study_design_scores_gemma":[0.0050991187,0.051478982,0.9309587,0.00009771744,0.0010461145,0.0006974609,0.00023705458,0.0024391485,0.0027299055,0.00033178506,0.0048538013,0.000030342437],"about_ca_topic_score_codex":0.0013261575,"about_ca_topic_score_gemma":0.0030280838,"teacher_disagreement_score":0.0015658849,"about_ca_system_score_codex":0.00039097102,"about_ca_system_score_gemma":0.00036869175,"threshold_uncertainty_score":0.005238354},"labels":[],"label_agreement":null},{"id":"W7117316366","doi":"10.1016/j.iotech.2025.101405","title":"408P Calpain as a novel therapeutic target in breast cancer","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Calpain Protease Function and Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen's University","funders":"","keywords":"Breast cancer; Calpain; Cancer; Human breast; Disease","score_opus":0.0045596551760820276,"score_gpt":0.28193680031661134,"score_spread":0.2773771451405293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117316366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7651346,0.16462606,0.030517446,0.0068790787,0.0010755343,0.00029703576,0.0005723991,0.0006301341,0.03026766],"genre_scores_gemma":[0.9348155,0.04097831,0.010089158,0.0007465543,0.0002996377,0.00013085434,0.00046652058,0.000047314672,0.01242606],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999261,0.000013052957,0.000003826332,0.000013255958,0.00002164367,0.000022113447],"domain_scores_gemma":[0.99996495,0.000008017195,0.000006672057,0.0000034880068,0.000007708584,0.000009062452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030918673,0.0004375738,0.0002482301,0.00031399578,0.00018827003,0.00050583587,0.00039222118,0.00054910197,0.0016339802],"category_scores_gemma":[0.00014790741,0.00015939631,0.00022021022,0.0002618196,0.00024126178,0.00036967508,0.00023431984,0.0009425706,0.0005095153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071470905,0.0002911918,0.0003726002,0.0003080418,0.000020768395,0.0006053432,0.000048253583,0.0004548423,0.9325353,0.0032131742,0.0014600434,0.05997572],"study_design_scores_gemma":[0.00040262472,0.0023170381,0.0030247048,0.000048573012,0.00008728938,0.003189089,0.000050775932,0.0026044426,0.9240274,0.0017668903,0.062465895,0.000015389764],"about_ca_topic_score_codex":0.00035250868,"about_ca_topic_score_gemma":0.00045002482,"teacher_disagreement_score":0.0016339802,"about_ca_system_score_codex":0.0004914824,"about_ca_system_score_gemma":0.00027261116,"threshold_uncertainty_score":0.005466163},"labels":[],"label_agreement":null},{"id":"W7117317538","doi":"10.1016/j.iotech.2025.101406","title":"409P Spatial profiling of tumour-infiltrating B cells reveals immune shifts in rapidly progressing cholangiocarcinoma","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Terry Fox Foundation","keywords":"Immune system; Antibody; Profiling (computer programming); Gene expression profiling; B cell; Phenotype","score_opus":0.012269400713676503,"score_gpt":0.3009349530357847,"score_spread":0.2886655523221082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117317538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973162,0.00036099367,0.0007585762,0.000019455574,0.000003424436,0.0000034134086,0.00010571505,0.000014872916,0.0014172643],"genre_scores_gemma":[0.9979474,0.0002024015,0.0005661552,0.00001989475,0.0000040482787,0.000009570234,0.00012504116,0.00000790954,0.0011175968],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999355,0.00000960823,0.000003704649,0.000013956074,0.000011400408,0.000025732461],"domain_scores_gemma":[0.999938,0.000014663209,0.000012137264,0.000008331547,0.0000115295425,0.000015240768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011364196,0.000100195284,0.00009921326,0.00046450362,0.00016453258,0.00030504778,0.00010544918,0.00020933368,0.0021195647],"category_scores_gemma":[0.0001462054,0.00011499631,0.00010476293,0.00031245462,0.00019444885,0.00019513979,0.0001839215,0.00026830626,0.00054028805],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050844677,0.000016961825,0.0073109553,0.00002380622,0.0000064365463,0.00019667218,0.00006920685,0.00007635068,0.9884114,0.000116308576,0.00004018773,0.0032232234],"study_design_scores_gemma":[0.00003030417,0.0006334661,0.3742373,0.000014354786,0.00006297887,0.0036499223,0.0010870255,0.0021103348,0.6124987,0.00057571026,0.0050853635,0.000014427043],"about_ca_topic_score_codex":0.00054030865,"about_ca_topic_score_gemma":0.0004937968,"teacher_disagreement_score":0.0021195647,"about_ca_system_score_codex":0.00010568967,"about_ca_system_score_gemma":0.000070905444,"threshold_uncertainty_score":0.0070906878},"labels":[],"label_agreement":null},{"id":"W7117320530","doi":"10.1016/j.iotech.2025.101565","title":"350P Demystifying the biology behind a high neutrophil-to-lymphocyte ratio in gastroesophageal adenocarcinoma patients","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; McGill University Health Centre","funders":"","keywords":"Adenocarcinoma; Disease; Cancer; MEDLINE; Esophageal adenocarcinoma","score_opus":0.00567843413252664,"score_gpt":0.29341565284709265,"score_spread":0.287737218714566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117320530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9685324,0.016319863,0.0021275932,0.0031380248,0.00030057726,0.000054023192,0.00042343463,0.00012401945,0.008980069],"genre_scores_gemma":[0.9951615,0.0016321796,0.0010563792,0.0005554048,0.00023493267,0.000024071102,0.00019326655,0.000009553934,0.0011328346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99976236,0.00006669907,0.000026278789,0.000035468027,0.00006275151,0.000046440084],"domain_scores_gemma":[0.99954337,0.00014417793,0.00012058873,0.000028256341,0.00009591241,0.00006768906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046101882,0.00032580152,0.00034095763,0.00066081894,0.00027837974,0.0010656833,0.00025870078,0.00052790064,0.0019403287],"category_scores_gemma":[0.0014008398,0.00012760797,0.00017056886,0.00057686353,0.00032965545,0.0006313385,0.00036205488,0.0007900775,0.00048645266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013488502,0.00013366844,0.86043483,0.0002185919,0.00009030513,0.0036166501,0.00028656467,0.00027416178,0.023977743,0.0011819339,0.0038853502,0.10455132],"study_design_scores_gemma":[0.000090963564,0.0011101718,0.9320228,0.00019995053,0.00030902683,0.015413399,0.0012436513,0.0030770889,0.021626484,0.0035315622,0.02133879,0.000036178146],"about_ca_topic_score_codex":0.0005400329,"about_ca_topic_score_gemma":0.0006588601,"teacher_disagreement_score":0.0019403287,"about_ca_system_score_codex":0.00029453618,"about_ca_system_score_gemma":0.00027191653,"threshold_uncertainty_score":0.006491065},"labels":[],"label_agreement":null}]}